The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy
The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy
复制标题
DOI：
10.1136/openhrt-2018-000993
复制
发表时间：
2019-01-01
期刊：
影响因子：
2.7
通讯作者：
Ilan, Yaron
中科院分区：
文献类型：
--
作者：
Forkosh, Esther;Ilan, Yaron
人类肠道微生物群已被确定为心血管疾病的一个可能的新风险因素。肠道微生物组在动脉粥样硬化和心力衰竭的发病机制中起作用。尽管对啮齿动物的研究表明肠道微生物可能会影响心脏病的风险，但这种联系尚未在人类中得到证实。在本研究中，我们回顾了肠道微生物组和细菌易位与心脏疾病发展相关的几种潜在机制，使其成为这些疾病新治疗措施的潜在靶点。调节肠道微生物群作为改变疾病发病机制的机制是一个越来越受关注的领域。肠道微生物群的改变正在被探索作为减少与心脏疾病相关的风险因素的方法。
The human gut microbiota has been identified as a possible novel risk factor for cardiovascular disease. The intestinal microbiome plays a role in the pathogenesis of atherosclerosis and heart failure. Even though studies in rodents suggested that gut microbes may affect the risk of heart disease, this link has not been shown in humans. In the present study, we review several potential mechanisms by which the gut microbiome and bacterial translocation are associated with the development of cardiac disorders making them potential targets for novel therapeutic measures for these conditions. Modulation of the gut microbiota as a mechanism for altering the pathogenesis of disorders is an area of growing interest. Alteration in the gut microbiota is being explored as a method of reducing risk factors associated with cardiac diseases.